Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Touret, Franck, Driouich, Jean-Sélim, Cochin, Maxime, Petit, Paul Rémi, Gilles, Magali, Barthélémy, Karine, Moureau, Grégory, Mahon, Francois-Xavier, Malvy, Denis, Solas, Caroline, de Lamballerie, Xavier, Nougairède, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274277/
https://www.ncbi.nlm.nih.gov/pubmed/34265358
http://dx.doi.org/10.1016/j.antiviral.2021.105137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274277/
https://www.ncbi.nlm.nih.gov/pubmed/34265358
http://dx.doi.org/10.1016/j.antiviral.2021.105137

Ejemplares similares